Key result
Urinary CTSA/eGFR ratio accurately discriminates heart failure from controls with an AUC of ~0.89.
Why the study?
Heart failure lacks a simple, repeatable test for use outside specialist centres, and whether urinary lysosomal cathepsin A (CTSA) can help diagnose HF was unknown.
Does urinary cathepsin A (CTSA), interpreted with renal function (eGFR), accurately discriminate patients with heart failure from healthy controls?
Case-Control (n=108)
No
Does urinary cathepsin A (CTSA), interpreted with renal function (eGFR), accurately discriminate patients with heart failure from healthy controls?
Answers are grounded in this paper and cite their sources.
May support non-invasive HF detection; hypothesis-generating and requires prospective validation before clinical use.
Background Heart failure (HF) still lacks a simple, repeatable test that can be applied outside specialist centres. Urine collects protein changes linked to disease, but whether urinary lysosomal cathepsin A (CTSA) can help diagnose HF is unknown. We assessed urinary CTSA as a potential diagnostic marker for HF. Methods We enrolled 58 HF patients and 50 age- and sex-matched healthy controls. Urine from 10 patients and 10 controls was analyzed by 4D label-free quantitative (4D-LFQ) proteomics; the remaining samples were used for ELISA confirmation. Differentially expressed proteins were identified and subjected to Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein–protein interaction (PPI) analyses. CTSA abundance was measured by ELISA and evaluated by regression and receiver operating characteristic (ROC) analysis, with adjustment for renal function. Results 4D-LFQ identified 200 differentially expressed proteins (82 up- and 118 downregulated; fold change > 1.5, P < 0.05). Bioinformatic analysis highlighted CTSA, a lysosomal protease in the renin–angiotensin system. ELISA showed that urinary CTSA was higher in HF than in controls (median [IQR] 3055.43 [2498.33–3434.76] vs 2551.4 [2084.76–2785.9] pg/mL; P < 0.0001). The CTSA/eGFR ratio discriminated HF from controls (AUC 0.89, 95% CI 0.83–0.96; sensitivity 85.0%, specificity 81.25%). The association remained positive after adjustment for eGFR (β = 524.098, P = 0.001). PPI analysis placed CTSA at the centre of a cluster of co-expressed lysosomal hydrolases and peptidases. Conclusions Urinary CTSA is increased in HF and, when interpreted with renal function, performs as a non-invasive diagnostic marker. It complements blood-based assays and merits validation in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) conducted a case-control in Heart failure (n=108). Urinary lysosomal cathepsin A (CTSA) and CTSA/eGFR ratio vs. Age- and sex-matched healthy controls was evaluated on Urinary CTSA concentration (pg/mL) and diagnostic discrimination of heart failure via the urinary CTSA/eGFR ratio (AUC 0.89, 95% CI 0.83-0.96, p=<0.0001). Urinary cathepsin A was higher in heart failure than controls, and the CTSA/eGFR ratio discriminated heart failure with an AUC of 0.89.
Synapse has enriched 10 related papers. Consider them for comparative context: